Literature DB >> 25628505

Vortioxetine (brintellix): a new serotonergic antidepressant.

Andrew D'Agostino, Clayton D English, Jose A Rey.   

Abstract

Vortioxetine (Brintellix): a new serotonergic antidepressant.

Entities:  

Year:  2015        PMID： 25628505      PMCID： PMC4296590     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  13 in total

1.  Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.

Authors:  Benny Bang-Andersen; Thomas Ruhland; Morten Jørgensen; Garrick Smith; Kristen Frederiksen; Klaus Gjervig Jensen; Huailing Zhong; Søren Møller Nielsen; Sandra Hogg; Arne Mørk; Tine Bryan Stensbøl
Journal:  J Med Chem       Date:  2011-04-12       Impact factor: 7.446

2.  Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder.

Authors:  David S Baldwin; Thomas Hansen; Ioana Florea
Journal:  Curr Med Res Opin       Date:  2012-09-17       Impact factor: 2.580

3.  A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder.

Authors:  Jean-Philippe Boulenger; Henrik Loft; Ioana Florea
Journal:  J Psychopharmacol       Date:  2012-04-09       Impact factor: 4.153

Review 4.  Serotonergic drugs for depression and beyond.

Authors:  Stephen M Stahl; Clara Lee-Zimmerman; Sylvia Cartwright; Debbi Ann Morrissette
Journal:  Curr Drug Targets       Date:  2013-05-01       Impact factor: 3.465

5.  A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.

Authors:  Neven Henigsberg; Atul R Mahableshwarkar; Paula Jacobsen; Yinzhong Chen; Michael E Thase
Journal:  J Clin Psychiatry       Date:  2012-07       Impact factor: 4.384

6.  A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.

Authors:  Rakesh Jain; Atul R Mahableshwarkar; Paula L Jacobsen; Yinzhong Chen; Michael E Thase
Journal:  Int J Neuropsychopharmacol       Date:  2012-09-11       Impact factor: 5.176

Review 7.  Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

Authors:  L Citrome
Journal:  Int J Clin Pract       Date:  2013-10-25       Impact factor: 2.503

Review 8.  Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research.

Authors:  Pau Celada; Analía Bortolozzi; Francesc Artigas
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

9.  Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.

Authors:  Jean-Philippe Boulenger; Henrik Loft; Christina Kurre Olsen
Journal:  Int Clin Psychopharmacol       Date:  2014-05       Impact factor: 1.659

10.  Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.

Authors:  Mohammed Y Alam; Paula L Jacobsen; Yinzhong Chen; Michael Serenko; Atul R Mahableshwarkar
Journal:  Int Clin Psychopharmacol       Date:  2014-01       Impact factor: 1.659
View more
  16 in total

1.  Association of Hyponatraemia and Antidepressant Drugs: A Pharmacovigilance-Pharmacodynamic Assessment Through an Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.

Authors:  Faizan Mazhar; Marco Pozzi; Marta Gentili; Marco Scatigna; Emilio Clementi; Sonia Radice; Carla Carnovale
Journal:  CNS Drugs       Date:  2019-06       Impact factor: 5.749

2.  Vortioxetine exerts anti-inflammatory and immunomodulatory effects on human monocytes/macrophages.

Authors:  Maria Talmon; Silvia Rossi; Anna Pastore; Carlo Ignazio Cattaneo; Sandra Brunelleschi; Luigia Grazia Fresu
Journal:  Br J Pharmacol       Date:  2017-11-28       Impact factor: 8.739

3.  The role of aryl-topology in balancing between selective and dual 5-HT7R/5-HT1A actions of 3,5-substituted hydantoins.

Authors:  Katarzyna Kucwaj-Brysz; Rafał Kurczab; Ewa Żesławska; Annamaria Lubelska; Małgorzata Anna Marć; Gniewomir Latacz; Grzegorz Satała; Wojciech Nitek; Katarzyna Kieć-Kononowicz; Jadwiga Handzlik
Journal:  Medchemcomm       Date:  2018-05-08       Impact factor: 3.597

4.  Vortioxetine versus sertraline in metabolic control, distress and depression in Mexican patients with type 2 diabetes.

Authors:  Carlos Alfonso Tovilla-Zárate; Antonia Pérez-Mandujano; Iris Rubí Ramírez-González; Ana Fresan; Samuel Suarez-Mendez; Esteban Martínez-Villaseñor; Ester Rodríguez-Sánchez; Mario Villar-Soto; María Lilia López-Narváez; Thelma Beatriz González-Castro; Jorge L Ble-Castillo; Isela Esther Juárez-Rojop
Journal:  Ann Transl Med       Date:  2019-11

5.  Using genetic drug-target networks to develop new drug hypotheses for major depressive disorder.

Authors:  Héléna A Gaspar; Zachary Gerring; Christopher Hübel; Christel M Middeldorp; Eske M Derks; Gerome Breen
Journal:  Transl Psychiatry       Date:  2019-03-15       Impact factor: 6.222

6.  Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.

Authors:  Takeshi Inoue; Kiyofumi Sasai; Tadayuki Kitagawa; Akira Nishimura; Isao Inada
Journal:  Psychiatry Clin Neurosci       Date:  2019-12-18       Impact factor: 5.188

Review 7.  The Potential Role of the Pharmacist in Supporting Patients with Depression - A Literature-Based Point of View.

Authors:  Maria Kamusheva; Desislava Ignatova; Anna Golda; Agnieszka Skowron
Journal:  Integr Pharm Res Pract       Date:  2020-02-26

Review 8.  The Pharmacology of Visual Hallucinations in Synucleinopathies.

Authors:  Mirella Russo; Claudia Carrarini; Fedele Dono; Marianna Gabriella Rispoli; Martina Di Pietro; Vincenzo Di Stefano; Laura Ferri; Laura Bonanni; Stefano Luca Sensi; Marco Onofrj
Journal:  Front Pharmacol       Date:  2019-12-09       Impact factor: 5.810

9.  A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction.

Authors:  Richard S E Keefe; George Nomikos; Wei Zhong; Michael Cronquist Christensen; William Jacobson
Journal:  Int J Neuropsychopharmacol       Date:  2018-05-01       Impact factor: 5.176

10.  Association of sleep among 30 antidepressants: a population-wide adverse drug reaction study, 2004-2019.

Authors:  Andy R Eugene
Journal:  PeerJ       Date:  2020-03-11       Impact factor: 2.984
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.